TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02642523
Drug: Nesiritide
Normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
Study: NCT02642523
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
Study: NCT05885386
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ was administered orally at an initial daily dose of 150 mg/m2 per day for 5 days, every 28 days preoperatively. In patients with a good tolerance during the first cycle, the dose was increased to 200 mg/m2 per day for 5 days, every 28 days.
Study: NCT05513469
Drug: Lutathera
Normalized name: Lutathera
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: regulair PRRT of 4 cycles with 7.4GBq
Study: NCT06176885
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with Camrelizumab monoclonal antibody will be administered after the initial two cycles of induction therapy.
Study: NCT04334408
Drug: Fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive a single dose total 225 mg (1 injection of 225 mg per 1.5 mL injection) followed by a single dose of 225 mg (1 1.5mL injection) at four week intervals. Both the subject and the investigator will be blinded to the timing of transition to and from placebo and the transition to and from fremanezumab.
Study: NCT04608682
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The muscle relaxant infusion will be discontinued and a bolus of sugammadex (2mg/kg) will be given while performing TceMEPs.
Study: NCT04608682
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The muscle relaxant infusion will be discontinued and 2ml saline will be infused, TceMEPs monitoring will be performed 5 minutes later.
Study: NCT03437330
Drug: Empagliflozin (Jardiance®)
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin Dose/frequency: 10 mg once daily for 12 weeks Route of administration: oral Reference group: Insulin glargine (Lantus®) Dose/frequency: see below FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +4 IU (stop when FBG is reduced by 1.0 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +6 IU (stop when FBG is reduced by 1.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)
Study: NCT03437330
Drug: Insulin Glargine (Lantus®)
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: insulin glargine shall be titrated according to the following scheme: If FBG 6-7 mmol/L: reduce fasting glucose by 0.5 mmol/L If FBG 7-8 mmol/L: reduce fasting glucose by 0.75 mmol/L~If FBG 8-9 mmol/L: reduce fasting glucose by 1.0 mmol/L Thus, insulin glargine doses should be adapted as follows:~FBG 6-7 mmol/L: +2 IU (stop when FBG is reduced by 0.5 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG 7-8 mmol/L: +3IU (stop when FBG is reduced by 0.75 mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs) FBG \> 8 mmol/L: +5 IU (stop when FBG is reduced by 1.0mmol/L or documented hypoglycemia \< 3.9 mmol/L occurs)
Study: NCT04736394
Drug: APL-1202
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL-1202 single-agent oral treatment
Study: NCT04736394
Drug: Epirubicin Hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epirubicin hydrochloride
Study: NCT05425368
Drug: Silver diamine fluoride
Normalized name: silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First permanent molars in this group will receive 38% silver diamine fluoride as an indirect pulp capping material.
Study: NCT05425368
Drug: Mineral trioxide aggregate
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First permanent molars in this group will receive mineral trioxide aggregate as an indirect pulp capping material.
Study: NCT05317858
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab infusion
Study: NCT05793632
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients will be randomly divided into two equal groups group Q and group C. Randomization will be done by computer-generated number lists and using opaque sealed envelopes.
Study: NCT04720287
Drug: bupivacaine/ neostigmine.
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive bilateral ultrasound guided QLB
Study: NCT04720287
Drug: bupivacaine/ neostigmine.
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive ultrasound guided CB.
Study: NCT04494113
Drug: Triapine
Normalized name: Triapine
DrugBank: Triapine (DB11940)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05171660
Drug: Sintilimab Injection
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab Injection: 200 mg, i.v., D1, Q3W, 8 courses
Study: NCT05289557
Drug: Bonjesta
Normalized name: Bonjesta
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release tablets contain 20 mg of doxylamine succinate and 20 mg of pyridoxine hydrochloride. Minimum 1 tablet at bedtime. Up to two pills daily (one tablet in the morning and one tablet at bedtime). The treatment duration is 15 days.
Study: NCT05285605
Drug: Ulipristal Acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ulipristal acetate 30mg x 1 dose as needed for unprotected intercourse
Study: NCT04848779
Drug: Alglucosidase alfa GZ419829
Normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: Lyophilized powder for solution~Route of administration: intravenous
Study: NCT06051409
Drug: Olverembatinib
Normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, once every other day (QOD).
Study: NCT06051409
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Orally, once daily (QD).
Study: NCT05425745
Drug: Obicetrapib
Normalized name: Obicetrapib
DrugBank: Obicetrapib (DB14890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg Obicetrapib tablet
Study: NCT04158635
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04158635
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04158635
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT04687241
Drug: Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of Almonertinib 110 mg daily can be reduced to 55 mg daily under specific conditions.
Study: NCT04687241
Drug: Placebo Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Almonertinib
Study: NCT05812612
Drug: ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To study the incidence of COVID-19 infection and COVID-19 pneumonia in patients with autoimmune liver disease treated by UDCA, and to explore the impact of UDCA on COVID-19 infection, disease occurrence and clinical outcome.
Study: NCT05916716
Drug: Amoxicillin 500mg
Normalized name: AMOXICILLIN 500MG CAP
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants enrolled in the PR +CAF+VCMX will be instructed to take amoxicillin 500mg (8 hours/8 hours, during 7 days) after the surgical procedures.
Study: NCT05916716
Drug: Sodium dipyrone
Normalized name: dipyrone
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will be instructed to take 500 mg sodium dipyrone just in case of pain.
Study: NCT06087276
Drug: 60 mg ulixacaltamide
Normalized name: Ulixacaltamide
DrugBank: Ulixacaltamide (DB18788)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily oral treatment with titration
Study: NCT06532409
Drug: Amoxicillin/CA
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive IV amoxicillin/CA at a dose of 100 mg per kg per day in 3 divided doses for a maximum period of 7 days.
Study: NCT06532409
Drug: IV ceftriaxone
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive IV ceftriaxone at a dose of 75 mg per kg per day in 2 divided doses for a maximum period of 7 days.
Study: NCT06616883
Drug: DA-5221_01
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (DA-5221_01 one tablet once a day)
Study: NCT06616883
Drug: DA-5221_01-R1 + DA-5221_01-R2
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose administration (DA-5221_01-R1 one tablet once a day + DA-5221_01-R2 one tablet once a day)
Study: NCT05567887
Drug: maplirpacept (PF-07901801)
Normalized name: Maplirpacept
DrugBank: Maplirpacept (DB18441)
Approvals — FDA: no, EMA: no, PMDA: no
Description: maplirpacept (PF-07901801)
Study: NCT05386056
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
Study: NCT05386056
Drug: Sinoporphyrin Sodium
Normalized name: Zinc mesoporphyrin
DrugBank: Zinc mesoporphyrin (DB17694)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2mg/kg, intravenously on day -2 of cycle 1.
Study: NCT04873869
Drug: NBI-921352
Normalized name: NBI-98782
DrugBank: NBI-98782 (DB16905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04979923
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine will be used for nebulization of the covid-19 patients and will be compared with other two drugs
Study: NCT06663631
Drug: chlorpromazine and promethazine
Normalized name: Chlorpromazine
DrugBank: Promazine (DB00420)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: C+P were diluted to 50 ml saline solution and delivered intravenously at the beginning of endovascular thrombectomyat a velocity of 4ml/h. The whole period of drug delivery lasts for approximately 12h.
Study: NCT05681819
Drug: SHR-1707
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-ascending Dose
Study: NCT05148754
Drug: Elsulfavirine
Normalized name: Elsulfavirine
DrugBank: Elsulfavirine (DB14929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elsulfavirin 200 mg tablets.
Study: NCT04899921
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous injection
Study: NCT04899921
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenously (IV) into the vein
Study: NCT04899921
Drug: Troriluzole
Normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally
Study: NCT05597839
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PD-1 immunotherapy agent
Study: NCT06674135
Drug: biosimilar insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
Study: NCT05719831
Drug: vonoprazan fumarate + high dose amoxicillin（H-10d）
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: vonoprazan fumarate 20 mg/time, 2 times/day, oral Amoxicillin 750mg/ time, 4 times/day, oral, for 10d
Study: NCT06663631
Drug: rt-PA
Normalized name: rt-PA
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients that are eligible for Intravenous thrombolysis will receive 0.9mg/kg rt-PA in aim to remove thrombus and restore reperfusion
Study: NCT04899492
Drug: Nicotine Replacement Therapy (NRT)
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive Nicotine Replacement Therapy (NRT) from randomization up to 6 months
Study: NCT06462144
Drug: IMPT-514 CART Cell Injection
Normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAR T-cell therapy administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
Study: NCT04770012
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients randomized to aspirin study group will be dispensed aspirin capsules to be taken daily for the duration of the treatment
Study: NCT04770012
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: patients randomized to clopidogrel study group will be dispensed clopidogrel capsules to be taken daily for the duration of the treatment
Study: NCT06494397
Drug: VHX-896 and iloperidone
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT06494397
Drug: Iloperidone and VHX-896
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet
Study: NCT05087212
Drug: plerixafor + G-CSF
Normalized name: G-CSF
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subcutaneous (SC) injection
Study: NCT05057468
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5-5 mg orally for 3 months
Study: NCT06001762
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4 and CDK6 inhibitor, tablet taken orally
Study: NCT06001762
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective estrogen receptor modulator, taken orally per institutional standard of care
Study: NCT06001762
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
Study: NCT06001762
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-steroidal aromatase inhibitor, taken orally per institutional standard of care
Study: NCT05057468
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/ m2 weekly dose for a maximum of 4 weeks
Study: NCT06001762
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroidal aromatase inhibitor, taken orally per institutional standard of care
Study: NCT06024967
Drug: PEG-somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-somatropin
Study: NCT06321055
Drug: Regorafenib (Stivarga, BAY73-4506)
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Retrospective analysis.
Study: NCT05740215
Drug: F520
Normalized name: F520
DrugBank: Rulonilimab (DB18922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: F520 is a recombinant, humanized programmed death receptor-1 (PD-1) monoclonal antibody that binds to PD-1 and prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)
Study: NCT05740215
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenvatinib capsules
Study: NCT05499416
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Self-administration of two (2-160 mg/mL \[1 mL\]) pre-filled syringes or autoinjectors at baseline (Day1) and at Weeks 4, 8,12, and 16
Study: NCT06398834
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In the esketamine combined with butorphanol group (Group BK), patients received an intraoperative intravenous infusion of esketamine (0.3 mg/kg/h) followed by postoperative patient-controlled intravenous analgesia (PCIA) (esketamine 1.5 mg/kg + butorphanol 0.15 mg/kg + azasetron 20 mg).
Study: NCT06398834
Drug: Butorphanol
Normalized name: Butorphanol
DrugBank: Butorphanol (DB00611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the butorphanol group (Group B), patients received an equivalent volume of normal saline intraoperatively and postoperatively received PCIA without esketamine.
Study: NCT04738838
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal treatment with oxytocin via nasal spray (48 IU per dose)
Study: NCT05557656
Drug: Regorafenib 40 MG
Normalized name: regorafenib 40 MG
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: participants who received the treatment of Regorafenib
Study: NCT05704673
Drug: nalbuphine on N and V and pain with intrathecal morphine onInguinal hernia repair surgery. randomized, prospective, double blinded and placebo-controlled trial study.
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: investigate the effect of Iv nalbuphine on postoperative nausea and vomiting and pain with intrathecal morphine on inguinal hernia repair surgery.
Study: NCT05622994
Drug: Rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
Study: NCT06444165
Drug: Lebrikizumab Pen
Normalized name: lebrikizumab Pen Injector
DrugBank: Lebrikizumab (DB11914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected into a practice pad.
Study: NCT04608630
Drug: Denosumab 60 MG/ML
Normalized name: denosumab 60 MG/ML
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients allocated to the Denosumab arm will receive Denosumab 60mg in 1ml, administered via subcutaneous injection on Study Days 1 and 180.
Study: NCT04608630
Drug: Sodium Chloride 0.9% or 5% Dextrose Intravenous
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients allocated to the placebo arm and Denosumab arm will receive 0.9% Sodium Chloride or 5% Dextrose 100ml administered via intravenous infusion over at least 15 minutes on Day 1.
Study: NCT04608630
Drug: Sodium Chloride 0.9% Injection
Normalized name: Sodium Chloride 0.9% Injection Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients allocated to the placebo arm and Zoledronic acid arm will receive 0.9% Sodium Chloride 1ml administered via subcutaneous injection on Days 1 and Day 180
Study: NCT04395469
Drug: 18F-FAZA
Normalized name: 18F-FAZA
DrugBank: Fluoroazomycin arabinoside F-18 (DB15134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-FAZA is a radiotracer used for PET imaging (in combination with MRI) to detect hypoxia in tumours. This scan will be done before and after radiation treatment.
Study: NCT04203433
Drug: DLX105-DMP
Normalized name: DMP-777
DrugBank: DMP-777 (DB18488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg applied to target lesion
Study: NCT05337644
Drug: Indocyanine green solution
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5 ml of ICG were then injected intravenously to identify the stomach, carefully assessing the angle of His (preoperative written informed consent was obtained from the patient).~Adequate perfusion was defined as the direct and clear visualization of the fluorescence around the gastric tube, after an estimated time of 150-180 s followingi.v. administration.
Study: NCT05367765
Drug: Flumatinib
Normalized name: Flumatinib
DrugBank: Flumatinib (DB11904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumatinib 600mg orally daily
Study: NCT05367765
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib 400mg orally daily (Reference drug instructions)
Study: NCT05116059
Drug: Amphotericin B colloidal dispersion（ABCD）
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The dosage and course of ABCD were determined by clinicians, and this study was registered according to clinical practice
Study: NCT06326528
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg or Empagliflozin 25mg
Study: NCT05327738
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05228249
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV